Current clinical trials and future studies should take into account gender-dependent factors, receptor polymorphism, and the selectivity of brain regions in order to optimize the translational potential of this strategy [114]
The 5-Day Fade: You might notice hunger returning slightly right before your next injection
Additional reporting by Nathaniel Meyersohn
Our doctors highlight the importance of addressing these lifestyle factors alongside medication
Scalability: Transition from small-scale synthesis to large scale manufacturing while maintaining consistency and quality is challenging AGENDA Accelerating Method Development and QC with LC-UV-MS for GLP-1 Agonists Steve Calciano Characterisation of GLP-1 Peptides and Impurities using HRMS and Ion Mobility Jon Fox Light Scattering solutions to analyse oligomeric state and aggregation in GLP-1 formulations Sophia Kenrick Bio-Analytical Quantification of GLP-1 Peptides: A Case Study on Semaglutide Henry Foddy Panel Discussion with All Speakers Why Attend
A new large-scale study from Truveta and collaborators from Providence, Johns Hopkins, Duke University, and more suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs)semaglutide and tirzepatidemay have another powerful benefit: reducing alcohol-related hospitalizations in people with alcohol use disorder (AUD)
